Armata Pharmaceuticals, Inc. (ARMP)

USD 1.95

(-2.5%)

Market Cap (In USD)

70.55 Million

Revenue (In USD)

4.52 Million

Net Income (In USD)

-69.04 Million

Avg. Volume

8363.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.95-4.48
PE
-
EPS
-
Beta Value
0.805
ISIN
US04216R1023
CUSIP
04216R102
CIK
921114
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Deborah L. Birx M.D.
Employee Count
-
Website
https://www.armatapharma.com
Ipo Date
1994-05-20
Details
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.